BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21929304)

  • 1. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
    Powell BL
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
    [No Abstract]   [Full Text] [Related]  

  • 2. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lo Coco F
    Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655
    [No Abstract]   [Full Text] [Related]  

  • 5. [Arsenic trioxide as a therapeutic agent in APL].
    Emi N
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():724-8. PubMed ID: 17474483
    [No Abstract]   [Full Text] [Related]  

  • 6. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
    Tallman MS
    Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparing two arsenic trioxide administration methods in APL therapy.
    Zhou J; Meng R; Yang BF
    Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
    Masamoto Y; Nannya Y; Arai S; Koike Y; Hangaishi A; Yatomi Y; Kurokawa M
    Br J Haematol; 2009 Mar; 144(5):798-9. PubMed ID: 19036092
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
    Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
    Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
    [No Abstract]   [Full Text] [Related]  

  • 10. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
    Zappasodi P; Rossi M; Ambaglio I; Bernasconi P; Corso A; Lazzarino M; Castagnola C
    Ann Hematol; 2011 May; 90(5):595-7. PubMed ID: 20721555
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
    Sui M; Zhang Z; Zhou J
    Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
    Tong H; Li K; Mei C; Wang H; Chen Z; Jin J
    Ann Hematol; 2011 Dec; 90(12):1493-4. PubMed ID: 21431323
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide.
    Au WY; Chim CS; Wai Lie AK; Pang A; Kwong YL
    Haematologica; 2002 Oct; 87(10):1109-11. PubMed ID: 12368167
    [No Abstract]   [Full Text] [Related]  

  • 17. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
    Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
    Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 19. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
    Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
    Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Lam MS; Ignoffo RJ
    Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.